Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung

Lung Cancer

Volumn 38, Issue 1, 2002, Pages 51-57

  Minami, Ken Ichiro ^a   Saito, Yukihito ^a   Imamura, Hiroji ^a   Okamura, Akiharu ^b  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b International Center for Diagnostic Pathology   (Japan)

Author keywords

18F FDG PET; Adenocarcinoma; Biological factors; Glut 1; Ki 67; Lung cancer; p53; Prognosis; VEGF

Indexed keywords

BIOLOGICAL FACTOR; GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN; PROTEIN P53; VASCULOTROPIN;

AGED; ANALYTIC METHOD; ANGIOGENESIS; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HAZARD ASSESSMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MALE; MICROVASCULATURE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

ADENOCARCINOMA; AGED; ENDOTHELIAL GROWTH FACTORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KI-67 ANTIGEN; LUNG NEOPLASMS; LYMPHOKINES; MALE; MIDDLE AGED; MONOSACCHARIDE TRANSPORT PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036805178     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00108-3     Document Type: Article

References (43)

1. Minna J.D. Wilson J.D., Braunwald E., Isselbacher K.J., et al. Harrison's principles of internal medicine. 14th ed. 1998;552-561 McGraw-Hill, USA.
2. Moore D.F., Lee J.S. Pass H.I., Mitchell J.B., Johnson D.H., et al. Lung cancer: principles and practice. 1996;481-494 Lippincott-Raven Publishers, Philadelphia.
3. West Japan Study Group for Lung Cancer Surgery (WJSG), Wada H., Hitomi S., Teramatsu T. Adjuvant chemotherapy after complete resection in non-small cell lung cancer. J. Clin. Oncol. 14:1996;1046-1054.
4. West Japan Study Group for Lung Cancer Surgery (WJSG), Wada H., Miyahara R., Tanaka F. Postoperative adjuvant chemotherapy with PVM (Cisplatin+Vindesine+Mitomycin C) and UFT (Uracil+Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): arandomized clinical trial. Eur. J. Cardio-thorac. Surg. 15:1999;438-443.
5. Tommaso C.M., Vincenzo A., Vincenzo C., et al. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer. Eur. J. Cardio-thorac. Surg. 20:2001;378-384.
6. Cagini L., Monacelli M., Giustozzi G., et al. Biological prognostic factor for early stage completely resected non-small cell lung cancer. J. Surg. Oncol. 74:2000;53-60.
7. Niklinski J., Niklinska W., Laudanski J., et al. Prognostic molecular markers in non-small cell lung cancer. Lung Cancer. 34:2001;S53-S58.
8. Thomas A.D.'A., Thomas A.A., Mary-Beth H., et al. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann. Thorac. Surg. 69:2000;882-886.
9. Mizera-Nyczak E., Dyszkiewicz W., Heider K.H., et al. Isoform expression of CD44 adhesion molecules, Bcl-2, p53 and Ki-67 proteins. Lung Cancer Tumor Biol. 22:2001;45-53.
10. The Japan Lung Cancer Society. General rule for clinical and pathological record of lung cancer. 5th ed. The Japan Lung Cancer Society. Tokyo: Kanehara, 1999. pp. 26-31.
11. Travis W.D., Colby T.V., Corrin B., et al. Histological typing of lung and pleural tumours, World Health Organization International histological classification of tumours. 1999;Springer, Berlin.
12. 18F]FDG uptake in non-small cell lung cancer. Eur. J. Nucl. Med. 27:2000;1778-1785.
13. Matthews M.J., Kanhouwa S., Pickren J., et al. Frequency of residual and metastatic tumor in patients undergoing curative resection for lung cancer. Part 3. Cancer Chemother. Rep. 4:1973;63-67.
14. Lung Cancer Study Group, Feld R., Rubinstein L.V., Weisenberger T.H., et al. Site of recurrence stage I non-small-cell lung cancer: a guide for future study. J. Clin. Oncol. 2:1984;1352-1358.
15. Pairolero P., Williams D., Bergstralh M., et al. Post-surgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann. Thorac. Surg. 38:1984;331-338.
16. Lau C.L., D'Amoco T.A., Harpole D.H. Staging and prognosis: clinical and molecular prognostic factors and models for non-small cell lung cancer. Pass H.I., Michell J.B., Johnson D.H., Turrisi A.T., et al. Lung cancer: principles and practice. 2nd ed. 1999;Lippincott Williams and Wilkins, Philadelphia.
17. Quinlan D.C., Davidson A.S., Summers C.L., et al. Accumulation of p53 correlates with a poor prognosis in human lung cancer. Cancer Res. 52:1992;4828-4831.
18. Fujno M., Dosaka-Akita H., Harada M., et al. Prognostic significance of p53 and ras p-21 expression in non-small cell lung cancer. Cancer. 76:1995;2457-2463.
19. Mclaren R., Kuzu I., Dunnill M., et al. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br. J. Cancer. 66:1992;735-738.
20. Brambilla E., Gazzeri S., Moro D., et al. Immunohistochemical study of p53 in human lung carcinomas. Am. J. Pathol. 143:1993;199-210.
21. Tomizawa Y., Kohno T., Fujita T., et al. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene. 18:1999;1007-1014.
22. Tubiana M., Courdi A. Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long-term survival. Radiother. Oncol. 15:1989;1-18.
23. Tungekar M.F., Gatter K.C., Dunnil M.S., et al. Ki-67 immunostaining and survival in operable lung cancer. Histopathology. 19:1991;545-550.
24. Pence J.C., Kerns B.J., Dodge R.K., et al. Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch. Surg. 128:1993;1382-1390.
25. Scagliotti G.V., Micela M., Gubetta L., et al. Prognostic significance of Ki67 labelling in resected non small cell lung cancer. Eur. J. Cancer. 29:1993;363-365.
26. Harpole D.H., Herndon J.E., Wolfe W.G., et al. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res. 55:1995;51-56.
27. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:1990;4-6.
28. Blood C.H., Zetter B. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim. Biophys. Acta. 1032:1990;89-118.
29. Folkman J. Tumor angiogenesis. Adv. Cancer Res. 43:1985;175-203.
30. Senger D.R., van de Walter L., Brown L.F., et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12:1993;303-324.
31. Angeletti C.A., Lucchi M., Fontanini G., et al. Prognostic significance of tumoral angiogenesis in completely resected lata stage lung carcinoma (stage IIIA-n2). Cancer. 78:1996;409-415.
32. Pezzella F., Di Bacco A., Andreola S., et al. Angiogenesis in primary lung cancer and lung secondaries. Eur. J. Cancer. 32:1994;2494-2500.
33. Niklinska W., Burzykowski T., Chyczewski L., et al. Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis. Lung cancer. 34:2001;S59-S64.
34. Han H., Silverman J.F., Santucci T.S., et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann. Surg. Oncol. 8:2001;72-79.
35. Baillie R., Carlile J., Pendleton N., et al. Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer. J. Clin. Pathol. 54:2001;116-120.
36. Yano T., Tanikawa S., Fujie T., et al. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur. J. Cancer. 36:2000;601-609.
37. Younes M., Brown R.W., Stephenson M., et al. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer. 80:1997;1046-1051.
38. Younes M., Lechago L.V., Somoano J.R., et al. Wide expression of the human erythrocyte glucose transporter Glut1 in human cancer. Cancer Res. 56:1996;1164-1167.
39. Merrall N.W., Plevin R., Gould G.W. Growth factors, mitogens, oncogenes, and the regulation of glucose transport. Cell Signal. 5:1993;667-675.
40. Brown R.S., Leung J.Y., Paul L.K., et al. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J. Nucl. Med. 40:1999;556-565.
41. Higashi T., Tamaki N., Torizuka T., et al. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J. Nucl. Med. 39:1998;1727-1735.
42. Higashi T., Tamaki N., Honda T., et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J. Nucl. Med. 38:1997;1337-1344.
43. Reske S.N., Grillenberger K.G., Glatting G., et al. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J. Nucl. Med. 38:1997;1344-1348.